Tvardi Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	20.73	31.61	22.92	21.49
Short-Term Investments	10.08	-	-	22.25
Cash & Short-Term Investments	30.81	31.61	22.92	43.74
Cash Growth	-2.54%	37.94%	-47.60%	-
Prepaid Expenses	0.73	0.07	3.24	0.37
Total Current Assets	31.54	31.69	26.16	44.11
Property, Plant & Equipment	0.2	0.3	0.38	0.46
Other Intangible Assets	0.32	0.39	0.45	0.51
Long-Term Deferred Charges	-	2.81	-	-
Other Long-Term Assets	0.02	0.02	0.02	0.02
Total Assets	32.07	35.2	27	45.1
Accounts Payable	3.22	2.19	1.61	2.41
Accrued Expenses	7.71	8.08	1.58	1.79
Current Portion of Leases	0.12	0.1	0.09	0.08
Total Current Liabilities	11.04	10.37	3.28	4.28
Long-Term Debt	-	30.26	-	-
Long-Term Leases	0.09	0.2	0.28	0.37
Total Liabilities	11.13	40.83	3.56	4.65
Common Stock	0.01	0	0.02	0.02
Additional Paid-In Capital	131.38	1.1	0.76	0.45
Retained Earnings	-110.45	-92.24	-62.84	-45.49
Comprehensive Income & Other	0.01	-	-	-0.02
Total Common Equity	20.95	-91.13	-62.06	-45.05
Shareholders' Equity	20.95	-5.63	23.45	40.45
Total Liabilities & Equity	32.07	35.2	27	45.1
Total Debt	0.2	30.56	0.37	0.45
Net Cash (Debt)	30.61	1.05	22.55	43.29
Net Cash Growth	2812.46%	-95.34%	-47.91%	-
Net Cash Per Share	3.93	0.41	3.54	6.79
Filing Date Shares Outstanding	9.38	6.4	6.38	6.37
Total Common Shares Outstanding	9.38	6.4	6.38	6.37
Working Capital	20.5	21.32	22.88	39.83
Book Value Per Share	2.23	-14.24	-9.73	-7.07
Tangible Book Value	20.62	-91.52	-62.51	-45.56
Tangible Book Value Per Share	2.20	-14.30	-9.80	-7.15

Source: S&P Capital IQ. Standard template. Financial Sources.